지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2001.12
- 수록면
- 216 - 223 (8page)
이용수
초록· 키워드
오류제보하기
Objectives : This open prospective study was performed in order to evaluate the efficacy and extrapyramidal adverse effects of nemonapride in the schizophrenic patients, and was compared with one of typical antipsychotics, haloperidol and one of atypical antipsychotics, risperidone.
Methods : Thirty male and female schizophrenic patients(DSM-Ⅳ) were treated for 12 weeks with haloperidol(n=10), risperidone(n=10) and nemonapride(n=10). The overall efficacy was assessed at baseline, 1st week, 2nd week, 4th week, 8th week, and 12th week by the Positive and Negative Syndrome Scale for Schizophrenia(PANSS). Also the overall safety was assessed in the same time period by the Extrapyramidal Symptom Rating Scale(ESRS).
Results : There were no significant differences in PANSS scores(total, positive, negative, and general psychopathology subscale) among haloperidol, risperidone, and nemonapride groups. Treatment responders, defined as at least 20% reduction of baseline total PANSS score, were achieved by 8 patients(80%) in haloperidol group, 10 patients(100%) in risperidone group, and 8 patients(80%) in nemonapride group. And there were no significant differences in ESRS total scores among haloperidol, risperidone, and nemonapride groups. Inter-group comparison among haloperidol, risperidone and nemonapride group, as assessed by the ESRS, revealed no significant differences in the shifts to the maximum score, 9.4(±9.4), 6.2(±8.4), and 11.3(±8.1) respectively, and also revealed no significant differences in the mean time reaching the maximum score, 4.5(±4.5) week, 7.8(±4 8) week, and 4.6(±4.4) week, respectivily.
Conclusion : There were no significant differences in the efficacy and extrapyramidal adverse effects among haloperidol, risperidone and nemonapride groups. These results suggest that nemonapride was as efficacious and safe in the treatment of schizophrenia, as well known and widely used antipsychotics, haloperidol and risperidone.
Methods : Thirty male and female schizophrenic patients(DSM-Ⅳ) were treated for 12 weeks with haloperidol(n=10), risperidone(n=10) and nemonapride(n=10). The overall efficacy was assessed at baseline, 1st week, 2nd week, 4th week, 8th week, and 12th week by the Positive and Negative Syndrome Scale for Schizophrenia(PANSS). Also the overall safety was assessed in the same time period by the Extrapyramidal Symptom Rating Scale(ESRS).
Results : There were no significant differences in PANSS scores(total, positive, negative, and general psychopathology subscale) among haloperidol, risperidone, and nemonapride groups. Treatment responders, defined as at least 20% reduction of baseline total PANSS score, were achieved by 8 patients(80%) in haloperidol group, 10 patients(100%) in risperidone group, and 8 patients(80%) in nemonapride group. And there were no significant differences in ESRS total scores among haloperidol, risperidone, and nemonapride groups. Inter-group comparison among haloperidol, risperidone and nemonapride group, as assessed by the ESRS, revealed no significant differences in the shifts to the maximum score, 9.4(±9.4), 6.2(±8.4), and 11.3(±8.1) respectively, and also revealed no significant differences in the mean time reaching the maximum score, 4.5(±4.5) week, 7.8(±4 8) week, and 4.6(±4.4) week, respectivily.
Conclusion : There were no significant differences in the efficacy and extrapyramidal adverse effects among haloperidol, risperidone and nemonapride groups. These results suggest that nemonapride was as efficacious and safe in the treatment of schizophrenia, as well known and widely used antipsychotics, haloperidol and risperidone.
목차
영어 초록
서론
연구대상 및 방법
결과
고찰
참고문헌
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
정신분열병의 급성 치료에서 리스페리돈과 할로페리돌의 치료 효과와 추체외로 부작용
생물치료정신의학
2000 .06
-
정신분열증환자에서 Nemonapride와 Haloperidol의 치료결과 및 내약성에 대한 비교분석
생물정신의학
1995 .01
-
RISPERIDONE VERSUS HALOPERIDOL IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS : A PARALLEL GROUP DOUBLE-BLIND COMPARATIVE TRIAL
대한임상약리학회 학술대회
1992 .01
-
정형 및 비정형 항정신병약물투여후 백서뇌내 Dopamine수용체의 변화
생물치료정신의학
2000 .12
-
정신분열증 환자 치료에서 Risperidone과 Haloperidol의 사용시 치료 비용 비교
생물치료정신의학
2002 .12
-
Nemonapride 및 Olanzapine 투여 후 정신분열병 환자의 혈장 Homovanillic Acid 농도의 변동
생물치료정신의학
2002 .06
-
만성 정신분열병 환자에서 Risperidone과 Clozapine이 체중과 혈당에 미치는 영향 - Haloperidol과의 비교 연구 -
생물정신의학
2004 .01
-
Haloperidol과 bethanechol 병합사용시 혈장 haloperidol 및 reduced haloperidol 농도에 미치는 영향
생물정신의학
1998 .01
-
정신분열병 또는 정신분열형장애를 가진 입원환자에서 Risperidone과 Olanzapine의 효과의 비교 : 6주간의 개방적 전향적 연구
생물치료정신의학
2003 .12
-
Plasma Concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
대한임상약리학회 학술대회
2001 .01
-
만성정신분열증 환자에 대한 리스페리돈 장기투여 2례
생물치료정신의학
1995 .12
-
DOUBLE-BLIND COMPARISON OF RISPERIDONE AND HALOPERIDOL : THERPAPEUTIC EFFICACY IN THE TREATMENT OF FIRST-ONSET SCHIZOPHRENIFORM DISORDER
대한임상약리학회 학술대회
1992 .01
-
급성 정신분열병 환자에 대한 Risperidone(R 64766)의 임상 효과 및 안정성 연구
한국응용약물학회 신약개발 연구발표회
1993 .01
-
정상 성인에서 Haloperidol이 정신생리적 기능에 미치는 영향
생물치료정신의학
1996 .12
-
소아 청소년 정신과 입원 환자에서 Risperidone의 효과 및 안정성에 관한 연구
소아청소년정신의학
2005 .09
-
SERUM HALOPERIDOL LEVEL AND CLINICAL EFFECTS IN CHRONIC SCHIZOPHRENIA
대한임상약리학회 학술대회
1993 .01
-
Risperidone이 백서의 억제된 자발적 교대 행동에 미치는 영향
생물치료정신의학
1998 .12
-
BIOEQUIVALENCE EVALUATION OF RISPERIDONE 2 MG TABLETS IN HEALTHY MALE KOREAN VOLUNTEERS
대한약학회 학술대회
2003 .01
-
섬망 환자의 치료에서 Haloperidol과 Quetiapine의 효과 비교 : 전향성 개방 연구
생물치료정신의학
2006 .12
-
HALOPERIDOL로 치료중인 정신분열병 환자에서 RIFAMPIN 병용 및 금단이 HALOPERIDOL 혈중농도 및 임상상태에 미치는 영향
대한임상약리학회 학술대회
1993 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2009-513-017218405